Lacprodan BLG-100 Helps Dietary Control Of Chronic Kidney Disease.

Arla Foods Ingredients is showing the efficacy of its novel protein component Lacprodan® BLG-100 (purified beta-lactoglobulin) in treating Chronic Kidney Disease (CKD).

CKD is a steady deterioration in kidney function that may ultimately result in End-Stage Renal Disease (ESRD). It affects about 850 million individuals globally and is responsible for one million fatalities annually1, with these numbers predicted to grow. CKD patients find it more challenging to maintain enough protein consumption while avoiding excessive intake of minerals such as phosphorus, potassium, sodium, and calcium as their renal functions decline.

To show how manufacturers may produce products to assist CKD patients, Arla Foods Ingredients is offering two solutions including Lacprodan® BLG-100: a ready-to-drink (RTD) beverage with 7% protein and a shot format with 21% protein.

The RTD has been scientifically formulated with 7% protein, 10% fat, and 20% carbs to assist those with Chronic Kidney Disease, stages 1 to 5, who are not on dialysis. Utilizing Lacprodan® BLG-100 reduces the phosphorous level of the low viscosity beverage relative to the vast majority of other commercially available options.

The second alternative is a high-protein shot solution that has been designed particularly for the nutritional management of CKD patients on dialysis who have fluid restriction or high protein needs. This application is great for aiding in the regulation of phosphorous levels in the body while also supplementing the diet with high-quality protein.

Mads Dyrvig, Head of Health and Performance Sales Development, said, “Minerals are important to life, but if your body has a diminished ability to expel it, an excess of minerals might be harmful. Many of the foods we consume, such as meat and dairy, are high in phosphorous, posing a dietary difficulty for those with CKD. People diagnosed with CKD are recommended to severely restrict their protein consumption. Phosphorus buildup in the body of a CKD patient raises the risk of heart attacks and strokes and may lead to cardiovascular illness, while the alternative is limiting protein consumption and progressively losing considerable muscle mass (muscle atrophy). Both disorders raise the likelihood of death, whereas muscular atrophy diminishes patients’ quality of life.

The bulk of commercially available Oral Nutritional Supplements (ONS) include quite high levels of minerals, including phosphorus. This market need may be filled by Arla Foods Ingredients’ Lacprodan® BLG-100, which is low in minerals, has an outstanding nutritional profile, and provides substantial muscle preservation advantages.”

“Because our BLG component is rich in vital amino acids and leucine, it provides high-quality proteins that satisfy the dietary demands of CKD and ESRD patients. It is also exceptionally low in phosphorous, making it an ideal ingredient for medical nutrition products since it provides protein supplementation without breaching low-mineral consumption requirements.”

Earlier this year, Arla Foods Ingredients’ Novel food application for Lacprodan® BLG-100 got a favourable opinion from the European Food Safety Authority (EFSA), indicating that it is safe and acceptable for use in food products in the EU. Furthermore, Lacprodan® BLG-100 was just awarded the 2022 Breakthrough Award for Dairy Ingredient Innovation by the American Dairy Products Institute (ADPI).